UBS Reaffirms Their Hold Rating on BioNTech SE (BNTX)

In a report released yesterday, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTXResearch Report), with a price target of $168.00. The company’s shares closed yesterday at $143.05.

Merle covers the Healthcare sector, focusing on stocks such as BioNTech SE, Madrigal Pharmaceuticals, and uniQure. According to TipRanks, Merle has an average return of -4.4% and a 40.66% success rate on recommended stocks.

Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $191.44, representing a 33.83% upside. In a report released on January 31, Goldman Sachs also maintained a Hold rating on the stock with a $156.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $188.99 and a one-year low of $117.08. Currently, BioNTech SE has an average volume of 966.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More